Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05212246 · ClinicalTrials.gov registry record · Phase 3
Basal Cell Carcinoma Chemoprevention Trial
A Phase 3 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,630
- Enrollment target
NCT05212246: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT05212246 is a Phase 3 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 1,630 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05212246, a Phase 3 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,630 participants
- Enrollment target
Study Summary
This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.
Primary Outcome
Skin exams will occur at baseline and at 6-month intervals after study randomization. Diagnosis of a new BCC will be ascertained by a biopsy under local anesthesia in an outpatient setting, as is the standard of care. Every biopsy performed on the face of a participant during the trial will be processed per standard clinical operating procedures, as determined by their blinded clinician for the purposes of patient management. The biopsy will be sent for reading by a blinded central dermatopathol
Interventions
- DRUG 5% Imiquimod cream
- DRUG Placebo Vehicle Control Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,630 participants |
| Start Date | 2026-08-03 |
| Est. Completion | 2032-08-03 |
| Phase | Phase 3 |
What is known before NCT05212246 opens enrollment
NCT05212246 is an interventional study that assigns participants to a tested intervention. Its 1,630 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which 5% Imiquimod cream is the first listed.
NCT05212246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05212246 about?
NCT05212246 is a clinical study titled "Basal Cell Carcinoma Chemoprevention Trial". This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will app...
What is the current status of trial NCT05212246?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,630 participants. The study started on 2026-08-03. Estimated completion is 2032-08-03.
What interventions are being tested in trial NCT05212246?
The interventions under investigation include: 5% Imiquimod cream (DRUG), Placebo Vehicle Control Cream (DRUG).
Who is sponsoring clinical trial NCT05212246?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05212246's enrollment target sits among peer trials
1,630 141st of 2000 higher than 1,860 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI